Radonova
After smoking, radon is the most common cause of lung cancer. Each year, it is estimated that about 230,000 people are affected globally as they stayed in places with elevated radon levels. With customers in 80 countries, Radonova Group is a global leader in measurement of radon in houses, apartment blocks and at workplaces.
Radonova in Lagercrantz Group
When Lagercrantz acquired Radonova in 2015, the annual business volume had been stable at around MSEK 35 with good profitability for several years. The subsidiary management and board developed a growth strategy, which involved several investments and the management was strengthened with Business Control and competencies in digitalisation. Internationally, Radonova’s business in Chicago was co-located with several other Lagercrantz companies, which created additional resources. In other markets, several new distributors were chosen and a digital platform for sales in Northern and Central Europe was added. New product investments as well as smaller supplementary acquisitions have added complementary products, and investments were also made in production in the form of, new robot equipment for the laboratory, among other things. Today Radonova is a world leader in radon measurement and both growth and profitability have gained momentum. During the pandemic, the growth rate declined somewhat but during the 2021/22 financial year it accelerated again and sales are now approaching MSEK 100. Since 2018, the EU Radiation Protection Directive applies, which for the first time includes action requirements for radon. The directive is enabling Radonova to continue expanding in the European market. The potential for expansion is increasing due to cooperation agreements recently entered into with several national public authorities, for example in Austria, Poland and Belgium.
“With Lagercrantz as owner, we have been able to specialise in radon measurement, we have developed our products and sales channels, and above all our digital platforms, which strongly contributed to the company’s performance in recent years.” Karl Nilsson, MD
Published: September 2022